Scientific Pillars

Activating the ability of immune cells to recognize and kill cancer cells

Enhancing or modulating T-cell and other immune effector cell responses, strengthening antigen presentation, and reprogramming tumor-microenvironment are strategies that are being employed to promote anti-tumor activity against a variety of cancers

Pursuing innovative targeted approaches

Crafting molecules to inhibit oncogenic drivers with a high degree of specificity. Creating therapies and combinations that target intrinsic and acquired resistance, for a potentially more durable response

Exploiting pathway dependencies to potentially induce cancer death

Targeting DNA damage response (DDR) dependencies, exploiting high levels of tumor replication stress and enhancing tumor sensitivity to DNA-damaging chemotherapies and radiation therapy to identify novel molecules with the potential to induce cancer cell death

Enabling selective delivery of cytotoxic payloads to tumors.

Arming tumor-targeted antibodies with chemotherapy to maximize the therapeutic potential of cytotoxic agents

Building a pipeline of innovative cell Chimeric Antigen Receptor T cell (CAR-T) and T Cell Receptor (TCR) therapies designed to empower and equip the immune system’s T-cells to more effectively fight cancer

Redirecting the immune system to eliminate cancer

T cell engagers are a type of bispecific antibody engineered to activate and redirect the immune system’s T cells to recognize and kill cancer cells

A novel approach to deliver targeted radiation directly to cancer cells.

Arming tumor-targeted molecules with payloads that emit ionizing radiation, inducing DNA double strand breaks to the DNA helix, leading to cell death.

Novel approaches to target cancer’s epigenome

Designing next generation small molecule inhibitors that reprogram cancer cells, by targeting epigenetic mechanism such as DNA, RNA and/or histone modifications, with potential to combine with other therapies to deepen response and overcome resistance mechanisms